Instituto Bioclon S.A. de C.V.
13
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.7%
1 terminated/withdrawn out of 13 trials
92.3%
+5.8% vs industry average
38%
5 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Decrease in Temperature as a Pagtonomic Sign by Scorpion Sting
Role: collaborator
Comparison of Lysine Clonixinate, Ketorolac and Metamizole Sodium in Scorpion Stings
Role: collaborator
A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco
Role: lead
Black Widow Spider Antivenin for Patients With Systemic Latrodectism
Role: lead
Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation
Role: lead
A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,
Role: lead
Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation
Role: lead
The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism
Role: lead
Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
Role: lead
Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.
Role: lead
Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients
Role: lead
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
Role: lead
Establishment of Natural History of Scorpion Envenomation
Role: lead
All 13 trials loaded